Sydney, Australia 2 May 2023
Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce the appointment of Dr Othon Gervasio as Senior Medical Director, effective immediately.
Dr Gervasio is an experienced senior leader with over 20 years in Research and Development (academic and clinical research) and Medical Affairs. His most recent role was Medical Director at Novartis, Australia and New Zealand. Dr Gervasio has worked for 13 years at Novartis and was involved in a wide range of projects, including clinical trials in oncology, the launch of several oncology products in various platforms, medical affairs strategy for therapies from pre-clinical to late-stage clinical development, as well as pre- and post-marketing authorisation.
Clarity’s Executive Chairman, Dr Alan Taylor, commented, “We are very pleased to welcome Othon to our team at this exciting time for Clarity. His extensive expertise in the oncology field and clinical trials will be highly valuable as our Targeted Copper Theranostic (TCT) products move closer to commercialisation. Our unique platform allows for the development of myriad products and can be optimised to treat various cancers while leveraging the many benefits of the copper platform, including clinical, manufacturing and logistical benefits. We look forward to working together with Othon to reach our ultimate goal of developing next-generation radiopharmaceuticals that will improve treatment outcomes for children and adults with cancer.”
Dr Othon Gervasio commented, “I am thrilled to be joining Clarity at this important time as it is preparing to launch its first Phase III trial in prostate cancer. The unique TCT platform, which allows the same chemical entity for both treatment and diagnosis of cancer, enables a true theranostic approach, differentiating Clarity from other companies in the radiopharmaceutical space. This innovative approach has shown great progress and encouraging results so far, and the copper paradigm holds great promise of expanding radiopharmaceuticals’ share in the large oncology market and improving treatment outcomes for people with cancer. I look forward to working together with the team at Clarity to fully explore the benefits of the TCT platform and develop new products to achieve timely access for patients with cancer in need of new treatments.”
About Clarity
Clarity is a clinical stage radiopharmaceutical company focused on the treatment of serious disease. The Company is a leader in innovative radiopharmaceuticals, developing targeted copper theranostics based on its SAR Technology Platform for the treatment of cancer in children and adults.
www.claritypharmaceuticals.com
Media Contact
Clarity Pharmaceuticals
Dr Alan Taylor
Executive Chairman
+61 (0)413 871 165
ataylor@claritypharm.com
Citadel-MAGNUS
Catherine Strong
Investor/Media Relations
+61 (0)406 759 268
cstrong@citadelmagnus.com
This announcement has been authorised for release by the Executive Chairman.
